Advertisement

Pharmaceutisch Weekblad

, Volume 14, Issue 3, pp 159–160 | Cite as

Studies on 2-n-propyl-2(E)-pentenoate (Δ2(E)-valproate) in man

  • Lennart Gram
Recent Developments on Valproate and its Metabolites

Keywords

Public Health Internal Medicine Valproate Pentenoate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Keane PE, Simiand J, Morre M. Comparison of the pharmacological and biochemical profiles of valproic acid (VPA) and its cerebral metabolite (2-en-VPA) after oral administration in mice. Methods Find Exp Clin Pharmacol 1985;7:83–6.PubMedGoogle Scholar
  2. 2.
    Löscher W. Anticonvulsant acitivity of metabolites of valproic acid. Arch Int Pharmacodyn 1981;249:158–63.PubMedGoogle Scholar
  3. 3.
    Löscher W. Pharmacologic, toxicologic and neurochemical effects of 2-n-propyl-2-pentenoate in animals. Pharm Weekbl [Sci];14(3A):139–43.Google Scholar
  4. 4.
    Düsing R. Single-dose tolerance and pharmacokinetics of 2-n-propyl-2-pentenoate in healthy male volunteers. Pharm Weekbl [Sci];14 (3A):152–8.Google Scholar
  5. 5.
    Löscher W, Nau H. Distribution of valproic acid and its metabolites in various brain areas of dogs and rats after acute and prolonged treatment. J Pharmacol Exp Ther 1983;226:845–54.PubMedGoogle Scholar
  6. 6.
    Löscher W, Nau H, Siemes H. Penetration of valproate and its active metabolites into cerebrospinal fluid of children with epilepsy. Epilepsia 1988;29:311–6.PubMedGoogle Scholar
  7. 7.
    Gram L, Flachs H, Würtz-Jørgensen A, Parnas J, Andersen B. Sodium valproate, serum levels and clinical effect in epilepsy: a controlled study. Epilepsia 1979;20:303–12.PubMedGoogle Scholar
  8. 8.
    Egger J, Brett EM. Effect of sodium valproate in 100 children with special reference to weight. BMJ 1981;283:577–81.PubMedGoogle Scholar
  9. 9.
    Dinesen H, Gram L, Andersen T, Dam M. Weight gain during treatment with valproate. Acta Neurol Scand 1984;69:65–9.PubMedGoogle Scholar
  10. 10.
    Breum L, Astrup A, Gram L, Andersen T, Stokholm KH, Christensen NJ, et al. Metabolic changes during treatment with valproate in humans: implications for weight gain. Metabolism. In press.Google Scholar
  11. 11.
    Kesterson JW, Granneman GR, Machinist JM. The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies. Hepatology 1984;4:1143–52.PubMedGoogle Scholar
  12. 12.
    Kingsley E, Gray P, Tilman KG, Tweedale R. The toxicity of metabolites of sodium valproate in cultured hepatotocytes. J Clin Pharmacol 1983;23:178–85.PubMedGoogle Scholar
  13. 13.
    Whittle BA. Pre-clinical, teratological studies on sodium valproate and other anticonvulsants. In: Legg NJ, ed. Clinical and pharmacological aspects of sodium valproate (Epilim) in the treatment of epilepsy. Tunbridge Wells: MCS Consultants, 1976:105–10.Google Scholar
  14. 14.
    Löscher W, Nau H, Marescaux C, Vergnes M. Comparative evaluation of anticonvulsant and toxic potencies of valproic acid and 2-en-valproic acid in different animal models of epilepsy. Eur J Pharmacol 1984;99:211–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Nau H. Transfer of valproic acid and its main active unsaturated metabolite to the gestational tissue: correlation with neural tube defect formation in the mouse. Teratology 1986;33:21–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Simon D, Penny JK. Sodium di-n-propylacetate (DPA) in the treatment of epilepsy. Epilepsia 1975;16:549–73.PubMedGoogle Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1992

Authors and Affiliations

  • Lennart Gram
    • 1
  1. 1.Hvidovre HospitalUniversity Clinic of NeurologyHvidovreDenmark

Personalised recommendations